Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Pathophysiology and Treatment of Congestive Heart Failure

      , ,

      Cardiology

      S. Karger AG

      Pathophysiology, Congestive heart failure, Therapeutic targets

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pharmacotherapy of heart failure is likely to be most efficacious when individually tailored to the prevailing pathophysiological derangements. Their diagnostic definition and understanding of the mechanisms involved affords the greatest opportunity for their correction and retardation of further progression of the syndrome, together with related improvements in quality of life, reduction of morbid cardiovascular events and improvement in prognosis. Four approaches may be identified, each of which allows rational therapeutic intervention. The disordered contractile geometry of the failing ventricle gives rise to increased ventricular wall tension and myocardial hypertrophy. The phenotype change largely responsible for this progression may be retarded, halted, or even reversed by a reduction of the elevated ventricular pressure and volume induced by diuresis and/or systemic vasodilatation. Knowledge of the subcellular changes responsible for electromechanical coupling and subsequent myocardial cell contraction in the various stages of heart failure is still incomplete. Pharmacotherapeutic interventions with positive inotropic agents have not been universally clinically efficacious, though the digitalis glycosides and, more recently, drugs that increase the sensitivity of the contractile proteins to calcium appear to afford further opportunity as they do not increase myocardial energy expenditure. In this regard, reduction in heart rate is a major determinant of myocardial contractile performance. Vascular stiffness and reduced vasodilator capacity are intrinsic accompaniments of congestive heart failure and exert deleterious effects on the heart by increasing preload and afterload and on the regional circulations by reducing blood flow. The mechanisms responsible include increased activity of the sympathoadrenal and renin-angiotensin-aldosterone systems, as well as reduction of endothelium-derived relaxing factor and increased stiffness of the vascular wall due to oedema. These furnish important targets for vasodilator and diuretic therapy and specific interventions to correct endothelial dysfunction. There are marked morphological and functional alterations of skeletal muscle depending on the severity and duration of the heart failure. These changes, together with activity detraining, contribute to reduced exercise capacity, a primary clinical hallmark of the syndrome. Improvement in muscle blood flow by improvement in cardiac pumping function and vasodilatation of the systemic resistance vessels, together with physical training programmes, constitute the most rational therapeutic approach to this fourth feature of the syndrome of congestive heart failure.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-6001-6
          978-3-318-01948-3
          0008-6312
          1421-9751
          1994
          1994
          18 November 2008
          : 84
          : Suppl 2
          : 99-107
          Affiliations
          Medizinische Universitätsklinik, Innere Medizin III, Freiburg, Germany
          Article
          176462 Cardiology 1994;84:99–107
          10.1159/000176462
          7954551
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Categories
          Congestive Heart Failure: Session IIIB

          Comments

          Comment on this article